EMULATE

Company Snapshot

Founded: 1994
Entity Type: Private
Region: U.S.
Headquarter: Massachusetts, U.S.
Key Geographics: North America, Europe, Asia-Pacific, Rest of World
Corporate Address: 27 Drydock Ave, 5th floor Boston, Massachusetts 02210 U.S. +1-781-583-3515 https: //emulatebio.com/

Company Overview

Emulate Inc. develops technologies that mimic human biology, improve precision in medicine, and facilitate the development of applications for personalized health. Emulate was founded by the researchers team at the Wyss Institute, Harvard University. The company offers organ models in three tiers: biokit, guided, and community. The company’s organ models support cancer, microbiome, infectious diseases, cell and gene therapy, toxicology, neuroscience, and immunology research. The company is developing drug partnerships with pharmaceutical companies such as AstraZeneca, Merck, Johnson & Johnson, and Takeda.

EMULATE In Reports

Organ-on-a-Chip: Global Markets

BCC Research Report: Dive into organ on a chip market report includes global revenue for base year data of 2023 and estimated data for the forecast period 2024 through 2029.

Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets

BCC Research Market Analyst says global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029.

3D Cell Cultures: Technologies and Global Markets

BCC Research Market Analyst says global market for 3D cell culture is estimated to increase from $4.6 billion in 2023 to reach $14.8 billion by 2028 at a CAGR of 26.5% from 2023 through 2028.

Company's Business Segments

  • Products : Organ Chip Overview, Brain Chip, Colon Intestine Chip, Duodenum Intestine Chip, Kidney Chip, Liver Chip, Lung Chip, Platform, Consumables, BioKits, Software.
  • Services : Standard Services, Custom Services, Meet the Team, Contact Research Services.

Applications/End User Industries

  • Healthcare
  • Cells Diagnostics
  • Life Sciences
  • Reagents Industries
AI Sentiment